Core Viewpoint - *ST SAILONG is planning a change of control, with Hainan Yayi becoming the new controlling shareholder, which has led to a significant increase in the company's stock price due to market optimism about potential operational improvements [1][4][5]. Group 1: Change of Control - The current controlling shareholders, Cai Nanguai and Tang Lin, have signed a share transfer agreement with Hainan Yayi, transferring 14.16% of their shares at a price of 8 yuan per share, totaling approximately 199 million yuan [4]. - If the transaction is completed, *ST SAILONG will become a company without a controlling shareholder, as Hainan Yayi currently has no actual controller [1][4]. - The stock price of *ST SAILONG has surged, with a continuous five-day limit up, reaching 10.2 yuan per share and a total market capitalization of 1.795 billion yuan as of May 23 [4]. Group 2: Background of Hainan Yayi - Hainan Yayi was established on May 15 specifically for this transaction, and its partners include notable figures such as Chen Zhansheng, who is associated with the well-known Libai Group [1][7]. - The investment structure of Hainan Yayi includes a total contribution of 300 million yuan, with Chen Zhansheng and Qitong Fuyuan being significant limited partners [7][8]. Group 3: Financial Performance - *ST SAILONG is currently facing significant operational challenges, having been placed under delisting risk warnings due to financial losses, with a projected revenue of approximately 264 million yuan for 2024, down 15.15% year-on-year [10]. - The company reported a net loss of approximately 33.15 million yuan for 2024, marking a shift from profit to loss, and has experienced continuous losses over the past five years [10]. - In the first quarter of this year, *ST SAILONG reported a revenue of about 54.09 million yuan, a decrease of 22.16% year-on-year, with a net loss of approximately 1.04 million yuan [10].

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-029 赛隆药业集团股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示 1.赛隆药业集团股份有限公司（以下简称"公司"或"本公司"）于 2025 年 4 月 25 日披露了《2024 年年度报告》，经审计的年度报告数据显示，公司 2024 年度利润总额、净利润、扣除非经常性损益后的净利润三者均为负值，且扣除后 的营业收入低于 3 亿元。根据《深圳证券交易所股票上市规则》第 9.3.1 条规 定，公司股票交易于 2025 年 4 月 28 日被深圳证券交易所实施退市风险警示。若 公司 2025 年度出现《深圳证券交易所股票上市规则》第 9.3.12 条所规定的关于 终止公司股票上市交易的相关情形之一，公司股票将面临被终止上市的风险。 2.公司控股股东、实际控制人蔡南桂先生、唐霖女士于 2025 年 5 月 18 日与 海南雅亿共赢科技合伙企业（有限合伙）（以下简称"海南雅亿"） 签署了《关 于赛隆药业集团股份有限公司之股份转让协议》（以下简称《 ...

赛隆药业集团股份有限公司 简式权益变动报告书 上市公司名称：赛隆药业集团股份有限公司 股票简称：*ST 赛隆 股票代码：002898 上市地点：深圳证券交易所 信息披露义务人（一）：蔡南桂 住所/通讯地址：广东省珠海市香洲区吉大白莲路**** 信息披露义务人（二）：唐霖 住所/通讯地址：广东省珠海市香洲区石花东路**** 股权变动性质：股份减少（协议转让） 签署日期：二〇二五年五月 1 信息披露义务人声明 本部分所述词语或简称与本报告书"释义"所述词语或简称具有相同含义。 1、本报告书系信息披露义务人根据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司收购管理办法》《公开发行证券的公司信息披露内容 与格式准则第 15 号——权益变动报告书》及相关的法律、法规及部门规章的有 关规定编制。 2、信息披露义务人均为自然人，其签署本报告书不需要获得必要的授权和 批准。 3、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定，本 报告书已全面披露了信息披露义务人在赛隆药业集团股份有限公司中拥有权益 的股份变动情况。 截至本报告书签署之日，除本报告书披露的持股信息外，信息披露义务人没 有通过任何其他方 ...

赛隆药业集团股份有限公司 详式权益变动报告书 上市公司名称：赛隆药业集团股份有限公司 股票上市地点：深圳证券交易所 股票简称：*ST赛隆 信息披露义务人：海南雅亿共赢科技合伙企业（有限合伙） 住所/通讯地址：海南省海口市龙华区金宇街道南海大道豪苑路1号海 口中关村信息谷创新中心雨林空间孵化器2025-ZC-1758号 股份变动性质：股份增加（协议受让） 签署日期：二〇二五年五月 赛隆药业集团股份有限公司 详式权益变动报告书 信息披露义务人声明 本部分所述词语或简称与本报告书"释义"所述词语或简称具有相同含义。 一、本报告书系信息披露义务人根据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司收购管理办法》《公开发行证券的公司信息披露内容 与格式准则第15号——权益变动报告书》《公开发行证券的公司信息披露内容与 格式准则第16号——上市公司收购报告书》及相关的法律、法规及部门规章的有 关规定编制。 二、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定，本 报告书已全面披露信息披露义务人在赛隆药业集团股份有限公司拥有权益的股 份变动情况。 截至本报告书签署日，除本报告书披露的持股信息外，信息披 ...

上海荣正企业咨询服务（集团）股份有限公司 关于 赛隆药业集团股份有限公司 详式权益变动报告书 之 财务顾问核查意见 上海荣正企业咨询服务（集团）股份有限公司 二〇二五年五月 1 声 明 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司 收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15 号—— 权益变动报告书》、《公开发行证券的公司信息披露内容与格式准则第 16 号— —上市公司收购报告书》及其他相关法律、法规及部门规章的规定，上海荣正企 业咨询服务（集团）股份有限公司（以下简称"本财务顾问"）按照行业公认的 业务标准、道德规范，本着诚实守信、勤勉尽责的精神，就本次信息披露义务人 披露的《赛隆药业集团股份有限公司详式权益变动报告书》进行核查，并出具核 查意见。 为使相关各方恰当地理解和使用本核查意见，本财务顾问特别声明如下： 一、本财务顾问依据的有关资料由信息披露义务人提供。信息披露义务人已 做出声明，保证其所提供的所有文件、材料及口头证言真实、准确、完整、及时， 不存在任何重大遗漏、虚假记载或误导性陈述，并对其真实性、准确性、完整性 和合法性负责。 二、本财务顾问已按照规定 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示： 赛隆药业集团股份有限公司（以下简称"公司"或"本公司"）控股股东、 实际控制人蔡南桂先生、唐霖女士于 2025 年 5 月 18 日与海南雅亿共赢科技合伙 企业（有限合伙）（以下简称"海南雅亿"）签署了《关于赛隆药业集团股份有 限公司之股份转让协议》（以下简称《股份转让协议》），蔡南桂先生、唐霖女 士拟向海南雅亿转让其持有的公司 14.16%股份。同时，蔡南桂先生、唐霖女士承 诺自本次交易交割日起至其不再持有上市公司股份之日止，无条件且不可撤销地 承诺放弃行使其所持标的公司剩余股份所对应的除收益权和股票处置权之外的 全部股东权利，上述事项可能导致本公司控股股东及实际控制人发生变更。该事 项尚需取得深圳证券交易所合规性确认后方可实施，能否最终完成及完成时间尚 存在重大不确定性。敬请广大投资者关注相关公告并注意投资风险。 证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-028 赛隆药业集团股份有限公司 关于受让方海南雅亿共赢科技合伙企业（有限合 伙）完成工商变更登记暨公司控制权拟发 ...

Group 1 - The Helicobacter pylori concept sector increased by 1.28%, ranking fifth among concept sectors, with 48 stocks rising, including New World and Haisan Pharmaceutical reaching a 20% limit up [1] - Major gainers in the Helicobacter pylori sector included Zhongsheng Pharmaceutical, *ST Sailong, and others, with increases of 8.80%, 7.82%, and 3.77% respectively [1] - The sector saw a net inflow of 599 million yuan from main funds, with 34 stocks receiving net inflows, and five stocks exceeding 50 million yuan in net inflow [2] Group 2 - The top three stocks by net inflow in the Helicobacter pylori sector were Haisan Pharmaceutical (179 million yuan), Zhongsheng Pharmaceutical (177 million yuan), and Jiaoda Onlly (128 million yuan) [2] - The net inflow ratios for Zhongsheng Pharmaceutical, Jiaoda Onlly, and Haisan Pharmaceutical were 42.93%, 18.92%, and 15.92% respectively [3] - The overall performance of the Helicobacter pylori sector was supported by significant trading volumes, with Haisan Pharmaceutical achieving a turnover rate of 39.86% [3]

Core Viewpoint - The article discusses the significant changes in the control of Sailong Pharmaceutical Group Co., Ltd. (*ST Sailong, 002898) following the signing of a share transfer agreement, alongside the company's poor financial performance leading to a delisting risk warning. Group 1: Share Transfer and Control Change - The controlling shareholders, Cai Nanguai and Tang Lin, signed a share transfer agreement to sell 14.16% of the company's shares to Hainan Yayi, amounting to a total transaction value of RMB 199,297,640.00 at a price of RMB 8 per share [1] - Following the transaction, Hainan Yayi will become the controlling shareholder, and the company will have no actual controller since Hainan Yayi currently has no actual controller [1] - The shareholding structure will change significantly, with Cai Nanguai's shareholding dropping from 51.15% to 38.36%, and Tang Lin's from 5.47% to 4.10% [1] Group 2: Financial Performance - Sailong Pharmaceutical reported a revenue of RMB 263.57 million in 2024, a decrease of 15.15% compared to 2023, and a net loss of RMB 33.15 million, a decline of 447.67% year-on-year [2][3] - The company has been issued a delisting risk warning due to its negative net profit and revenue falling below RMB 300 million [3][4] Group 3: Regulatory Actions - The company received a warning letter from the Guangdong Securities Regulatory Bureau due to discrepancies between its earnings forecast and actual performance, as well as failure to disclose potential delisting risks in a timely manner [4][5] - Key executives, including the chairman and financial director, were held responsible for the company's non-compliance with disclosure regulations [5] Group 4: New Shareholder Background - Hainan Yayi, the acquiring entity, was established on May 15, 2025, specifically for this transaction and currently has no actual business operations [6] - The partnership structure of Hainan Yayi indicates that it lacks an actual controller, with decision-making requiring unanimous agreement among partners [8]

Market Overview - The Shanghai Composite Index is at 3389.00 points, above the six-month moving average, with a slight increase of 0.04% [1] - The total trading volume of A-shares today is 512.26 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 75 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Meirui New Materials (300848) with a deviation rate of 8.28% and a price increase of 8.72% [1] - Wankong Intelligent Manufacturing (603070) with a deviation rate of 7.52% and a price increase of 9.97% [1] - Hitec High-tech (002023) with a deviation rate of 5.81% and a price increase of 10.01% [1] Detailed Stock Performance - The following stocks have notable performance metrics: - Sichuan Jiuzhou (000801) with a price increase of 3.47% and a deviation rate of 2.56% [2] - Phoenix Light (600071) with a price increase of 3.05% and a deviation rate of 2.47% [2] - Raytheon Micro Power (301050) with a price increase of 4.04% and a deviation rate of 2.26% [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002898 证券简称：*ST赛隆（维权） 公告编号：2025-027 赛隆药业集团股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 特别风险提示 1.赛隆药业集团股份有限公司（以下简称"公司"或"本公司"）于2025年4月25日披露了《2024年年度报 告》，经审计的年度报告数据显示，公司2024年度利润总额、净利润、扣除非经常性损益后的净利润三 者均为负值，且扣除后的营业收入低于3亿元。根据《深圳证券交易所股票上市规则》第9.3.1条规定， 公司股票交易于2025年4月28日被深圳证券交易所实施退市风险警示。若公司2025年度出现《深圳证券 交易所股票上市规则》第9.3.12条所规定的关于终止公司股票上市交易的相关情形之一，公司股票将面 临被终止上市的风险。 2.公司控股股东、实际控制人蔡南桂先生、唐霖女士于2025年5月18日与海南雅亿共赢科技合伙企业 （有限合伙）（以下简称"海南雅亿"） 签署了《关于赛隆药业集团股份有限公司之股份转让协议》 （以下简称《 ...